Optiscan reveals its pathology imaging device Optiscan (ASX:OIL) has revealed a new microscopic imaging device that extends its product reach to pathology clinics.
Optiscan’s confocal laser endomicroscopy platform enables real-time imaging of tissue, avoiding the need for painful biopsies and analysing samples under an old-fashioned microscope.
Known as In Form – we’ll call it Inform – the tool promises to improve the “efficiency and accuracy of analysis and diagnosis across all pathology workflows”.
Inform will enable pathologists to make on-the-spot decisions, rather than wait for perhaps weeks for a lab report.
Optiscan chief Dr Camile Farah says pathology has lagged radiology and diagnostic imaging in adopting modern, end-to-end digital workflows.
That sounds a bit like those chemists with their faxes.
“Inform is designed to enhance the entire pathology workflow across a range of settings, enabling efficiencies and on-the-spot digital decision making for pathologists to improve diagnostic capabilities.”
Optiscan’s initial commercialisation plans centred on a tool called Invivage, for use by dentists.
The company submitted an approval application to the US Food & Drug Administration (FDA) in August 2022.
But the agency advised that because of the novel nature of the device, the process would take too long.
The company is prioritising development of a variant device, Invue, for real-time surgical guidance (surgeons don’t have to rely on their eyesight or fingers).
Invue’s development centres on a 50-patient breast cancer validation trial at the Royal Melbourne Hospital and Frances Perry House.
OIL Price at posting:
16.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)